Inspire Pharmaceuticals News

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Fitch also maintains the following debt ratings o... NEW YORK-- --Strategic Global Income Fund, Inc.

Inspire Pharmaceuticals, Inc. announced today patient enrollment is complete in three of its late-stage clinical trials.

Lionel Pincus, founder and chairman of New York-based private equity firm Warburg Pincus, has died, according to a spokesman for his longtime partner, Princess Firyal of Jordan.

Inspire Pharmaceuticals plans to pay $11 million to Yamasa Corp. over several years as part of a new licensing agreement that will allow it to secure a second supplier of a proposed cystic fibrosis treatment, according to an SEC filing made by Inspire.

InSite Vision Incorporated today announced that Inspire Pharmaceuticals, its commercial partner for AzaSite 1% in the U.S and Canada, has committed to increasing production of AzaSite in response to the manufacturing supply shortage of erythromycin ophthalmic ointment .

Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration and is increasing its production of AzaSite A 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment .

Sep 9, 2009 - Inspire Pharmaceuticals, Inc. announced today it received the North Carolina Health & Life Sciences Award in the category of "Breakthrough Research" for its denufosol tetrasodium program for cystic fibrosis .

BUYINS.NET, www.buyins.net, has reviewed the NASDAQ Daily Short Volume Report for Tuesday, September 1st, 2009 and come to the following statistical conclusions.

In an effort to help Triangle-area nonprofits navigate their way through the recession, the Triangle Community Foundation will hold a workshop in Chapel Hill Aug.

Investors can't seem to get enough of the huge payoff potential of investing in the Biotechnology industry, as the industry starts to raise capital once again various types of equity offerings.

Christy L. Shaffer's latest Wall Street haul: $109 million. On Monday, her publicly traded Durham drug company, Inspire Pharmaceuticals, announced it had raised $115 million by selling 25.6 million new shares of its stock to investors for $4.50 each.

Christy L. Shaffer's latest Wall Street haul: $109 million. On Monday, her publicly traded Durham drug company, Inspire Pharmaceuticals, announced it had raised $115 million by selling 25.6 million new shares of its stock to investors for $4.50 each.

Christy L. Shaffer's latest Wall Street haul: $109 million. On Monday, her publicly traded Durham drug company, Inspire Pharmaceuticals, announced it had raised $115 million by selling 25.6 million new shares of its stock to investors for $4.50 each.

Christy L. Shaffer's latest Wall Street haul: $109 million. On Monday, her publicly traded Durham drug company, Inspire Pharmaceuticals, announced it had raised $115 million by selling 25.6 million new shares of its stock to investors for $4.50 each.

A week ago, long-time Inspire Pharmaceuticals Chief Executive Officer Christy Shaffer disclosed plans to leave her job once a successor is found.

So what does the CEO of a local publicly traded company do after her company raises $100 million in much-needed cash on Wall Street? She relaxes at the beach, naturally, but keeps her BlackBerry on.

Inspire Pharmaceuticals, Inc. announced today the pricing of its previously announced public offering of its common stock at a price to the public of $4.50 per share and an increase in the offering size to 22.2 million shares.

Futures were moving lower after the Challenger Layoffs report showed a 31% increase in layoff announcements in July and the ADP private-sector employment report showed a larger-than-expected increase in private sector job losses.

Christy Shaffer said last week that she would step down as Inspire's CEO. View Larger Inspire Pharmaceuticals announced after markets closed Tuesday that it wants to raise $80 million by selling common stock to the public.